. 2013 May 27;5(5):237–250. doi: 10.4254/wjh.v5.i5.237

Table 1.

The pre transplant hepatitis C virus antiviral therapy studies

Study	No.	Study design	Regime	Period	GFs	CTP/MELD mean	Genotype	Tx Naive	On Tx virolocal response %		SVR %		CessationTx	Dose reduction	% HCV neg post LTx²	Period FU postLTx
Study	No.	Study design	Regime	Period	GFs	CTP/MELD mean	Genotype	Tx Naive	G1/4	G2/3	G1/4	G2/3	CessationTx	Dose reduction	% HCV neg post LTx²	Period FU postLTx
Massoumi et al[28]	90	Cohort	90-180 mcg IFNα2a + 400-1200 mg RBV od	8 wk	Y	6.7/11.2	77% G1/4	62%	48	67	10	29	33%	18%	40%	9.6 mo
Massoumi et al[28]	90	Cohort	90-180 mcg IFNα2a + 400-1200 mg RBV od	8 wk	Y	6.7/11.2	77% G1/4	62%	48	67	10	29	33%	18%	(2/5)	9.6 mo
A2ALL LADR 2009¹	79	Prospective semirandomised	0.75 mcg/kg per wk PEG IFNα2b + 600 mg RBV od	11.4-14.6 wk	NA	NA	59% G1/4	NA	NA	NA	NA	NA	NA	75% adverse event	40%	3 mo
A2ALL LADR 2009¹	79	Prospective semirandomised	0.75 mcg/kg per wk PEG IFNα2b + 600 mg RBV od	11.4-14.6 wk	NA	NA	59% G1/4	NA	NA	NA	NA	NA	NA	75% adverse event	(2/5)	3 mo
Everson et al[23]	124	Cohort	IFNα2b 1.5-3 mu x 3/wk + RBV 600-1200 mg od	6-12 mo	Y	7.4/11	70% G1	NA	30	83	13	50	13%	71%	80% (12/15)	6 mo
Iacobellis et al[24]	66	Case match	PEG IFNα2b 1 mg/kg per wk + RBV 800-1000 mg od	24 wk	Y	8/14.2	67% G1/4	NA	30	83	7	44	20%	40%	0%	30 mo
Iacobellis et al[24]	66	Case match	PEG IFNα2b 1 mg/kg per wk + RBV 800-1000 mg od	24 wk	Y	8/14.2	67% G1/4	NA	30	83	7	44	20%	40%	(0/0)	30 mo
Crippin et al[30]	15	Randomised	IFNα2b 1-3 mu od/wk ± RBV 400 mg bd	12 wk	N	11.9/NA	73% G1	NA	18	10	NA		NA	87% adverse event (study closed)	0%	1 mo
Crippin et al[30]	15	Randomised	IFNα2b 1-3 mu od/wk ± RBV 400 mg bd	12 wk	N	11.9/NA	73% G1	NA	18	10	NA		NA	87% adverse event (study closed)	(0/0)	1 mo
Thomas et al[27]	20	Cohort	IFNα2b 5 mu od	14 mo	Y	12/13/2010	67% G1	100%	56	100	NA		0%	0%	33%	33.6 mo
Thomas et al[27]	20	Cohort	IFNα2b 5 mu od	14 mo	Y	12/13/2010	67% G1	100%	56	100	NA		0%	0%	(4/12)	33.6 mo
Forns et al[22]	30	Cohort	IFNα2b 3 mu od + RBV 800 mg od	12 wk	Y	50% CTP A, 50% B/C	83% G1	80%	30	82	NA		25%	63%	67%	46 wk
Forns et al[22]	30	Cohort	IFNα2b 3 mu od + RBV 800 mg od	12 wk	Y	50% CTP A, 50% B/C	83% G1	80%	30	82	NA		25%	63%	(6/9)	46 wk
Carrion 2009	51	Case match	PEG IFNα2a 180 mcg/wk + RBV 800-1200 mg od	15 wk	Y	48% CTP A, 43% B	88% G1/4, 10% G2/3	NA	47		20		43%	49%	67%	6 mo
Carrion 2009	51	Case match	PEG IFNα2a 180 mcg/wk + RBV 800-1200 mg od	15 wk	Y	48% CTP A, 43% B	88% G1/4, 10% G2/3	NA	47		20		43%	49%	(10/15)	6 mo
Tekin et al[31]	20	Cohort	PEG IFNα2a 135 mcg/wk + RBV 1-1.2 g od	48 wk	N	30% CTP A, 70% B	All G1b	NA	45	-	30	-	40%	65%	33%	14 mo
Tekin et al[31]	20	Cohort	PEG IFNα2a 135 mcg/wk + RBV 1-1.2 g od	48 wk	N	30% CTP A, 70% B	All G1b	NA	45	-	30	-	40%	65%	(1/3)	14 mo

Not published presented at American Association for the Study of Liver Diseases 2009. Substudy of Adult to Adult Living Donor Liver Transplant Study (A2ALL) low accelerated dose regime (LADR);

% hepatitis C virus (HCV) neg post LTx = Patient No. HCV neg post LTx/HCV neg at LTx (actual patient nos). GFs: Growth factors; CTP: Child Turcotte Pugh; MELD: Model for End Stage Liver Disease; Tx: Treatment; SVR: Sustained virological response; neg: negative; LTx: Liver transplant; FU: Follow up, mcg: Micrograms; IFN: Interferon; RBV: Ribavirin, od: Once daily; bd: Twice daily; Y: Yes; N: No NA: Not available.